Aou Senese - Uoc Ematologia E Trapianti
About Aou Senese - Uoc Ematologia E Trapianti
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gruppo Italiano Malattie EMatologiche dell'Adulto
24
Fondazione Italiana Linfomi ONLUS
9
Hoffmann-La Roche
4
Gruppo Italiano Trapianto di Midollo Osseo
2
Clinical Trials at Aou Senese - Uoc Ematologia E Trapianti
During the past decade, Aou Senese - Uoc Ematologia E Trapianti conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 6 clinical trials were completed, i.e. on
average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
2006-09-04
2011-05-26
Completed
545
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase
2007-06-23
2018-04-30
Completed
74
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
2008-02-01
2016-01-01
Completed
42
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
2008-11-03
2013-01-14
Completed
97
Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
2009-02-09
2014-10-10
Completed
129
Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
2008-07-01
2011-08-01
Completed
33
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
2010-03-01
2010-12-01
Completed
448
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Aou Senese - Uoc Ematologia E Trapianti"
#1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator and "GRADE Onlus" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Aou Senese - Uoc Ematologia E Trapianti
According to Clinical.Site data, the most researched conditions in "Aou Senese - Uoc Ematologia E Trapianti" are
"Chronic Lymphocytic Leukemia" (4 trials), "Acute Myeloid Leukemia" (3 trials), "Chronic Myeloid Leukemia" (3 trials), "Acute Lymphoid Leukemia" (2 trials) and "Follicular Lymphoma" (2 trials). Many other conditions were trialed in "Aou Senese - Uoc Ematologia E Trapianti" in a lesser frequency.
Clinical Trials Intervention Types at Aou Senese - Uoc Ematologia E Trapianti
Most popular intervention types in "Aou Senese - Uoc Ematologia E Trapianti" are "Drug" (31 trials), "Other" (9 trials) and "Genetic" (1 trials). Other intervention types were less common.
The name of intervention was led by "Imatinib" (3 trials), "Nilotinib" (3 trials), "Cyclophosphamide" (2 trials), "Lenalidomide" (2 trials) and "Ponatinib" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Aou Senese - Uoc Ematologia E Trapianti
The vast majority of trials in "Aou Senese - Uoc Ematologia E Trapianti" are
39 trials for "All" genders.
Clinical Trials Status at Aou Senese - Uoc Ematologia E Trapianti
Currently, there are NaN active trials in "Aou Senese - Uoc Ematologia E Trapianti".
undefined are not yet recruiting,
12 are recruiting,
8 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 18 completed trials in Aou Senese - Uoc Ematologia E Trapianti,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Aou Senese - Uoc Ematologia E Trapianti, 2 "Phase 1"
clinical trials were conducted, 18 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 1 trials that are defined as “Not Applicable".